Can kesimpta cause a reaction at the injection site?

Is Kesimpta likely to cause reactions at the injection site?

Kesimpta is given as a self-administered subcutaneous injection. Local skin reactions are a common side effect. These include redness, pain, swelling, and itching. Data show that 21.5 percent of patients in clinical trials experienced injection-site reactions, which usually appeared within 24 hours and lasted 1 to 5 days.

How serious are injection-site reactions with Kesimpta?

Most reactions stay mild to moderate and resolve without treatment. A few cases developed into cellulitis or abscesses that need antibiotics. Serious reactions occur less than 1 percent of the time. Patients who keep experiencing severe reactions may need to stop treatment.

Can you prevent or reduce injection-site reactions?

Proper injection technique helps. Patients should let the syringe reach room temperature before injecting, rotate sites each time, and avoid areas that are tender or damaged. Cold packs applied after the injection can help lind the pain. Some patients also use topical anesthetics.

When does a reaction warrant medical attention?

Seek care if the site develops increasing pain, spreading redness, pus, or fever. These signs suggest infection or a larger allergic reaction. Doctors usually advise patients to report any persistent or severe reactions.

Why are companies challenging this patent?

Novartis holds the core patents on ofatumumab, the active ingredient in Kesimpta. Generic manufacturers have filed paragraph IV certifications challenging those patents on invalidity and non-patentability grounds. The earliest possible launch of a generic version of Kesimpta is projected for 2030.

When does exclusivity expire?

Exclusivity granted under the biologics price competition and innovation act ends in 2032.